Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

NCT04179110 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding was withdrawn prior to first enrollment.

Conditions

Transitional Cell Carcinoma

Interventions

DRUG: Pembrolizumab and Ramucirumab

Sponsor

Yale University